NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Assess the Potential Impact of Disease Modifying Therapies on COVID-19 Outcomes and the Antibody Response Following an Infection With SARS-CoV-2 in Patients With Multiple Sclerosis Within the Swiss Multiple Sclerosis Cohort.

NCT04760990

CompletedN/A

Sponsor: University Hospital, Basel, Switzerland

Conditions: Multiple Sclerosis, COVID-19 (Severe Coronavirus Disease 2019)

Interventions: data collection, analysis of blood samples

Countries: Switzerland

This nested project of the Swiss Multiple Sclerosis Cohort (SMSC) is to assess the severity of COVID-19 and the magnitude of antibody response after infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in patients already treated or not with various immunotherapies for multiple sclerosis followed in the framework of the SMSC.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* all patients in the Swiss Multiple Sclerosis Cohort (SMSC)

Exclusion Criteria:

* Patients with Neuromyelitis optica and Radiologically Isolated Syndrome will be excluded
* Existence of a documented refusal of further use of health-related personal data and/or biological material

Locations (7)

Aarau, Switzerland
Basel, Switzerland
Bern, Switzerland
Geneva, Switzerland
Lausanne, Switzerland
Lugano, Switzerland
Sankt Gallen, Switzerland